PACOCF₃

A novel Ca²⁺-independent and reversible inhibitor of phospholipase A₂ (PLA₂; IC₅₀ = 3.8 µM). May also inhibit Ca²⁺-dependent PLA₂ at much higher concentrations (IC₅₀ = 45 µM).

A novel Ca²⁺-independent phospholipase A₂ inhibitor (IC₅₀ = 3.8 µM). May also inhibit Ca²⁺-dependent phospholipase A₂ at higher concentrations (IC₅₀ = 45 µM)

Cell permeable: no

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 3.8 µM and 45 µM against phospholipase A2 (PLA2) and Ca2+-dependent PLA2, respectively.

Toxicity: Standard Handling (A)

Following reconstitution in DMSO, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C. Product has a very low melting point. The product will change from a solid to a liquid if held in your hand or kept at room temperature or warmer for any period of time. It is best to keep the product cool while in use by placing it in the refrigerator or on ice during experimentation. Once diluted in buffer, do not store in aqueous solutions for >1 day.

Supplied as a solution in ethanol. To change the solvent, evaporate the ethanol with a stream of nitrogen and immediately reconstitute with the solvent of choice. Soluble in DMSO (30 mg/ml). Only minimally soluble in aqueous buffers; do not use basic buffers; unstable at basic pH.

Conde-Frieboes, K., et al. 1996. J. Am. Chem. Soc. 118, 5519.
Lio, Y.C., et al. 1996. Biochim. Biophys. Acta 1302, 55.
Ackermann, E.J., et al. 1995. J. Biol. Chem.270, 445.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany